YourChoice Therapeutics, Inc. is a biotechnology company focused on developing and manufacturing non-hormonal contraceptive products for women. Founded in 2018 and headquartered in Berkeley, California, the company has created a technology that utilizes an active compound to inhibit sperm motility, thereby preventing fertilization. This innovative approach aims to provide safer birth control options that eliminate the risks associated with traditional hormonal methods, offering users a solution with potentially fewer side effects. The company's commitment to advancing reproductive health is reflected in its focus on developing effective and safe contraceptive alternatives.
ALICE empowers construction engineering and management professionals with modern AI and Optimization techniques. Its software automatically produces detailed schedules and resource allocations, which accurately estimate the cost and time frame for a project. Users understand the construction process through an interactive visualization, and can quickly tweak or modify a schedule to reflect the shifting realities of the construction cycle. It is born out of research at Stanford by a collaborative effort between experienced construction managers, software engineers, and computational methods specialists. ALICE enhances construction planning and scheduling abilities to help keep crews flowing on any size project. It works directly with 3D BIM and using a simple rule-based system, it explores millions of different schedule sequences and gives teams the power to answer “What If?” scenarios and completely reschedule in just minutes. It was founded in 2013 and is headquartered in Menlo Park, California.
Osmind Inc. specializes in developing healthcare software tailored for mental health providers and their patients, particularly focusing on treatment-resistant mental health conditions. Founded in 2020 and based in California, the company aims to enhance clinical care and streamline workflows for providers through its innovative software solutions. Osmind's tools not only facilitate improved patient care but also support the advancement of novel therapeutics, precision diagnostics, and care management programs. The company's mission is to increase patient access to effective mental health treatments that can succeed where traditional therapies may not.
64x Bio is a biotechnology company based in San Francisco, California, founded in 2017 by Alexis Rovner, George Church, Jeffrey Way, and Pamela Silver. The company specializes in designing microorganisms with enhanced properties to facilitate advanced applications in biomanufacturing, bioremediation, and health. By creating cells tailored for specific purposes, 64x Bio aims to enable innovative solutions that were previously unattainable in these fields.
Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.
Gameto is a biotechnology company focused on addressing infertility and menopause-related challenges. Founded in 2020 and headquartered in New York, the firm employs a unique platform that utilizes proprietary combinations of transcription factors to create engineered ovarian cell lines. These cell lines are designed to replicate the functions of natural ovarian cells, allowing for the production and regulation of hormones essential for female reproductive health. By harnessing allogeneic human cellular derivatives, Gameto aims to develop therapeutic applications that can effectively treat conditions associated with accelerated ovarian aging and enhance assisted fertility options for women.
Ockam Inc. is a company that specializes in providing a serverless platform for secure Internet-of-Things (IoT) development. Founded in 2017 and headquartered in San Francisco, California, Ockam offers open-source tools that enable developers to create trustworthy IoT systems. Its platform facilitates the interconnection of hardware and software services, allowing for the secure exchange of information between connected devices and cloud services. Ockam's solutions include end-to-end encryption, key management, and mutual authentication, ensuring that data remains secure in transit across complex networks. By connecting application developers, system integrators, and hardware engineers, Ockam simplifies the development process and enhances the trustworthiness of data exchanged within IoT ecosystems.
Woola is a company that develops sustainable packaging solutions by utilizing leftover sheep wool to replace traditional plastic bubble wrap. Their innovative packaging materials are lightweight, protective, and compostable, allowing customers to significantly reduce plastic waste associated with online shopping. Woola's eco-friendly approach encourages a closed-loop system, wherein the wool-based packages can be reused, repurposed, or returned by end users, ensuring that nothing goes to waste.
New Culture Inc. is a food and beverage company that specializes in producing cheese from protein using innovative methods. By employing microflora to create dairy proteins and dairy products, the company aims to revolutionize traditional cheese-making processes. Founded in 2018 and headquartered in San Francisco, California, New Culture is committed to developing sustainable and alternative cheese options that appeal to a growing market of health-conscious and environmentally aware consumers.
Cambrian Biopharma is a multi-asset biotech R&D firm uniquely focused on a specific field of biomedical research: the biology of aging, also known as geroscience. We believe the future of medicine should be proactive and committed to extending our best years, not just reactive to certain diseases. As experts in the biology of age-related disease, it is our mission to assemble the world's best scientists to accelerate this paradigm shift. We are built on an emerging business model we call a "Distributed R&D Company" (or "DisCo"), partnering with academic geroscientists to build companies, conduct preclinical drug discovery, and manage clinical trials. Cambrian looks to discover and develop therapeutics that target the molecular damage that arises during aging and leads to chronic disease. Our approach is to build a diverse portfolio led by scientific rigor and data, not ego. Focusing on early-stage therapeutics, we collaborate with pioneering scientists to bring discoveries out of the lab and into the clinic as efficiently as possible. So far, we have launched 10 companies with leading geroscientists and have relationships with more than 100 geroscience-focused labs globally, translating to a toolkit for tech-transfer negotiations and rapid spinouts.
Developer of a climate mitigation platform designed for ecological restoration at a planetary scale. The company's platform develops a comprehensive tool for people all around the world to algorithmically determine the specific regenerative strategies for individual land parcels and landscape-level ecosystem regeneration, enabling clients to realize their land's full natural and economic potential.
Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.
Latent AI, Inc. develops a platform for optimization for edge devices that enables smart Internet of things (IoT) applications. It offers Latent AI Efficient Interence Platform (LEIP) that enables developers to train, quantize, and deploy edge AI neural networks. The company’s LEIP is designed for AI, embedded, and software application developers to enable, deploy, and manage AI for the edge. Latent AI, Inc. was incorporated in 2018 and is based in Menlo Park, California. It has additional office in Skillman, New Jersey.
Osmind Inc. specializes in developing healthcare software tailored for mental health providers and their patients, particularly focusing on treatment-resistant mental health conditions. Founded in 2020 and based in California, the company aims to enhance clinical care and streamline workflows for providers through its innovative software solutions. Osmind's tools not only facilitate improved patient care but also support the advancement of novel therapeutics, precision diagnostics, and care management programs. The company's mission is to increase patient access to effective mental health treatments that can succeed where traditional therapies may not.
Beeflow S.A. is a company that specializes in professional pollination services, focusing on the enhancement of bee health and efficiency. Founded in 2016 and headquartered in Buenos Aires, Argentina, Beeflow employs scientific techniques and organic compounds to improve the immune systems of bees, enabling them to effectively pollinate specific crops. The company has demonstrated significant success in increasing crop yields, with reported improvements ranging from 20% to 90% in various fruits such as blueberries, almonds, raspberries, and kiwifruit. Since its inception, Beeflow has expanded its operations to the United States and continues to grow its presence, particularly in Ventura County, California. The company's efforts aim to address the challenges of declining bee populations while supporting agricultural productivity.
MobileCoin, Inc., founded in 2017 and based in San Francisco, California, operates a cryptocurrency that emphasizes privacy and security in transactions. The platform utilizes blockchain technology to facilitate secure exchanges while ensuring user confidentiality. MobileCoin is designed to be easily integrated with mobile messaging applications such as WhatsApp, Facebook Messenger, or Signal, allowing users to access a MobileCoin wallet seamlessly. By combining distributed trust with a user-friendly experience, MobileCoin aims to enhance the way individuals conduct secure transactions in a digital environment.
Cambrian Biopharma is a multi-asset biotech R&D firm uniquely focused on a specific field of biomedical research: the biology of aging, also known as geroscience. We believe the future of medicine should be proactive and committed to extending our best years, not just reactive to certain diseases. As experts in the biology of age-related disease, it is our mission to assemble the world's best scientists to accelerate this paradigm shift. We are built on an emerging business model we call a "Distributed R&D Company" (or "DisCo"), partnering with academic geroscientists to build companies, conduct preclinical drug discovery, and manage clinical trials. Cambrian looks to discover and develop therapeutics that target the molecular damage that arises during aging and leads to chronic disease. Our approach is to build a diverse portfolio led by scientific rigor and data, not ego. Focusing on early-stage therapeutics, we collaborate with pioneering scientists to bring discoveries out of the lab and into the clinic as efficiently as possible. So far, we have launched 10 companies with leading geroscientists and have relationships with more than 100 geroscience-focused labs globally, translating to a toolkit for tech-transfer negotiations and rapid spinouts.
Cambrian Biopharma is a multi-asset biotech R&D firm uniquely focused on a specific field of biomedical research: the biology of aging, also known as geroscience. We believe the future of medicine should be proactive and committed to extending our best years, not just reactive to certain diseases. As experts in the biology of age-related disease, it is our mission to assemble the world's best scientists to accelerate this paradigm shift. We are built on an emerging business model we call a "Distributed R&D Company" (or "DisCo"), partnering with academic geroscientists to build companies, conduct preclinical drug discovery, and manage clinical trials. Cambrian looks to discover and develop therapeutics that target the molecular damage that arises during aging and leads to chronic disease. Our approach is to build a diverse portfolio led by scientific rigor and data, not ego. Focusing on early-stage therapeutics, we collaborate with pioneering scientists to bring discoveries out of the lab and into the clinic as efficiently as possible. So far, we have launched 10 companies with leading geroscientists and have relationships with more than 100 geroscience-focused labs globally, translating to a toolkit for tech-transfer negotiations and rapid spinouts.
Cambrian Biopharma is a multi-asset biotech R&D firm uniquely focused on a specific field of biomedical research: the biology of aging, also known as geroscience. We believe the future of medicine should be proactive and committed to extending our best years, not just reactive to certain diseases. As experts in the biology of age-related disease, it is our mission to assemble the world's best scientists to accelerate this paradigm shift. We are built on an emerging business model we call a "Distributed R&D Company" (or "DisCo"), partnering with academic geroscientists to build companies, conduct preclinical drug discovery, and manage clinical trials. Cambrian looks to discover and develop therapeutics that target the molecular damage that arises during aging and leads to chronic disease. Our approach is to build a diverse portfolio led by scientific rigor and data, not ego. Focusing on early-stage therapeutics, we collaborate with pioneering scientists to bring discoveries out of the lab and into the clinic as efficiently as possible. So far, we have launched 10 companies with leading geroscientists and have relationships with more than 100 geroscience-focused labs globally, translating to a toolkit for tech-transfer negotiations and rapid spinouts.
Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.
Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.
ATAI Life Sciences AG is a clinical-stage biopharmaceutical company headquartered in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative treatments for mental health disorders, addressing significant unmet medical needs. ATAI employs a decentralized, technology-driven platform model to accelerate the development of therapies. Its diverse portfolio includes product candidates such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and GRX-917 (Deuterated etifoxine), among others. By pooling expertise and resources, ATAI aims to create impactful, evidence-based therapies that can transform mental health treatment. The company operates primarily in Germany and the United States.
ALICE empowers construction engineering and management professionals with modern AI and Optimization techniques. Its software automatically produces detailed schedules and resource allocations, which accurately estimate the cost and time frame for a project. Users understand the construction process through an interactive visualization, and can quickly tweak or modify a schedule to reflect the shifting realities of the construction cycle. It is born out of research at Stanford by a collaborative effort between experienced construction managers, software engineers, and computational methods specialists. ALICE enhances construction planning and scheduling abilities to help keep crews flowing on any size project. It works directly with 3D BIM and using a simple rule-based system, it explores millions of different schedule sequences and gives teams the power to answer “What If?” scenarios and completely reschedule in just minutes. It was founded in 2013 and is headquartered in Menlo Park, California.
Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.
Taimei Technology specializes in developing cloud-based software solutions for clinical research and pharmacovigilance, aimed at enhancing efficiency in the biopharmaceutical industry. Founded in 2013 and headquartered in Jiaxing, China, the company offers a wide array of integrated solutions, including electronic data collection, drug randomization, electronic patient-reported outcomes, and medical imaging systems. Its platform supports collaboration among sponsors, clinical sites, contract research organizations (CROs), patients, and regulatory bodies, facilitating comprehensive clinical trial management and drug monitoring. Taimei Technology also provides additional services such as training, consulting, and outsourcing, catering to the needs of pharmaceutical companies and clinical research organizations. With offices in Shanghai and Beijing, Taimei Technology is dedicated to advancing the clinical research landscape through innovative technology.
Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.
Commonwealth Fusion Systems LLC is a research company focused on developing fusion energy as a sustainable solution to combat climate change. Established in 2017 and based in Cambridge, Massachusetts, the company utilizes advanced rare-earth barium copper oxide superconductor technology to create energy through fusion. Commonwealth Fusion Systems combines decades of government-funded fusion research with innovative superconducting magnet technology to expedite the commercialization of fusion energy. The company emerged from the Massachusetts Institute of Technology and collaborates closely with MIT’s Plasma Science and Fusion Center, leveraging extensive research to enhance its development efforts. By designing and building fusion machines, Commonwealth Fusion aims to provide limitless and clean energy, contributing to the global transition toward sustainable energy sources.
Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.
Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.
Ockam Inc. is a company that specializes in providing a serverless platform for secure Internet-of-Things (IoT) development. Founded in 2017 and headquartered in San Francisco, California, Ockam offers open-source tools that enable developers to create trustworthy IoT systems. Its platform facilitates the interconnection of hardware and software services, allowing for the secure exchange of information between connected devices and cloud services. Ockam's solutions include end-to-end encryption, key management, and mutual authentication, ensuring that data remains secure in transit across complex networks. By connecting application developers, system integrators, and hardware engineers, Ockam simplifies the development process and enhances the trustworthiness of data exchanged within IoT ecosystems.
The Boring Company is an infrastructure and tunnel construction firm established by Elon Musk in late 2016. The company focuses on efficiently digging tunnels to create an underground transportation network aimed at alleviating traffic congestion. Its services include the construction of tunnels that facilitate faster and more economical transportation options, addressing urban mobility challenges. By providing innovative tunneling solutions, The Boring Company seeks to improve the overall efficiency of transportation systems in congested areas.
Commonwealth Fusion Systems LLC is a research company focused on developing fusion energy as a sustainable solution to combat climate change. Established in 2017 and based in Cambridge, Massachusetts, the company utilizes advanced rare-earth barium copper oxide superconductor technology to create energy through fusion. Commonwealth Fusion Systems combines decades of government-funded fusion research with innovative superconducting magnet technology to expedite the commercialization of fusion energy. The company emerged from the Massachusetts Institute of Technology and collaborates closely with MIT’s Plasma Science and Fusion Center, leveraging extensive research to enhance its development efforts. By designing and building fusion machines, Commonwealth Fusion aims to provide limitless and clean energy, contributing to the global transition toward sustainable energy sources.
Latent AI, Inc. develops a platform for optimization for edge devices that enables smart Internet of things (IoT) applications. It offers Latent AI Efficient Interence Platform (LEIP) that enables developers to train, quantize, and deploy edge AI neural networks. The company’s LEIP is designed for AI, embedded, and software application developers to enable, deploy, and manage AI for the edge. Latent AI, Inc. was incorporated in 2018 and is based in Menlo Park, California. It has additional office in Skillman, New Jersey.
Mythic Inc. is a technology company that specializes in designing and developing silicon chips and artificial intelligence (AI) processing units. Founded in 2012 and headquartered in Redwood City, California, with an office in Austin, Texas, Mythic focuses on creating analog matrix processors that enable AI capabilities across a range of devices, from fitness bands and hearing aids to self-driving cars and robotic drones. The company’s flagship products include the M1076 Analog Matrix Processor and various PCIe and M.2 cards. Mythic's technology integrates hybrid digital and analog computations within flash arrays, providing desktop-grade compute power in a compact form factor while maintaining performance, energy efficiency, and accuracy. The company has assembled a diverse team of experts in neural networks, software design, and processor architecture to advance AI deployment in real-world environments.
Medcorder, Inc. develops medcorder, a mobile application that allows its users to record and transcribe complete conversations with their doctor and then share them with their family. Its application helps patients and their families to better communicate and coordinate care. The company's application also helps doctors by reducing the number of calls and repeated visits they get. The company’s application is compatible with Android and iOS. The company was founded in 2019 and is headquartered in Redwood City, California.